Articles

Videos

Podcasts

Clinical

Seizalam is a benzodiazepine indicated for the treatment of status epilepticus in adults.

Daily Medication Pearl: Seizalam

As local drug delivery technology evolves, the field is set for monumental change.

Advances in Glioblastoma Multiforme Shift the Treatment Paradigm 

Tardive dyskinesia is often caused by the use of dopamine receptor blocking agents, most commonly antipsychotics, for at least a few months.

Clinical Overview: Treatments for Tardive Dyskinesia 

A recent study revealed that social activities like gardening or getting a college degree could improve cognition in older age, which could possibly prevent Alzheimer disease. 

Study: Lifelong Learning Could Protect Against Alzheimer Disease

Currently, there is no treatment targeted for superoxide dismutase 1 amyotrophic lateral sclerosis, which has a life expectancy of 3 to 5 years from time of symptom onset.

FDA Accepts New Drug Application for Tofersen as Treatment of SOD1-ALS

They can assess for adherence, identify drug-related problems, monitor pharmacotherapy, and provide education.

Pharmacists Can Help Manage Patients With Parkinson Disease

Researchers highlight how a lack of access to medications used to treat multiple sclerosis, migraines, and epilepsy, but not proven safe for pregnancy, threatens child-bearing aged women who live with these conditions.

Abortion Ban Could Be Life-Threatening for Women With Neurological Conditions

Zonisade is the first and only FDA-approved oral liquid formulation of zonisamide, which helps patients with epilepsy who have difficulty swallowing tablets.

FDA Approves Zonisamide Oral Suspension as Adjunctive Therapy For Epilepsy 

Apomorphine (Kynmobi) is indicated for the acute, intermittent treatment of off episodes in patients with Parkinson disease.

Daily Medication Pearl: Apomorphine (Kynmobi)

Ofatumumab (Kesimpta) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis.

Neurology